• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.

    5/15/26 4:02:45 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    60 Degrees Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    83006G104

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    83006G104


    1Names of Reporting Persons

    Knight Therapeutics Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  (1) See item 4 below. This constitutes an exit filing for the Reporting Person.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    60 Degrees Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    1025 Connecticut Avenue, NW Suite 1000, Washington D.C. 20036
    Item 2. 
    (a)Name of person filing:

    Knight Therapeutics Inc.
    (b)Address or principal business office or, if none, residence:

    600 - 100 boul. Alexis Nihon Montreal, QC, H4M 2P2
    (c)Citizenship:

    Canada
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    83006G104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of March 31, 2026, the Reporting Person no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this Amendment No. 3 to Schedule 13G is being filed as an exit filing.
    (b)Percent of class:

    0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Knight Therapeutics Inc.
     
    Signature:/s/ Samira Sakhia
    Name/Title:Samira Sakhia
    Date:05/15/2026
    Get the next $SXTP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SXTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S bought $10,131 worth of shares (7,350 units at $1.38), increasing direct ownership by 44% to 24,131 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    6/15/26 4:50:47 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S bought $10,131 worth of shares (7,350 units at $1.38), increasing direct ownership by 44% to 24,131 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    6/15/26 4:50:47 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Francois Eric

    3 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    5/19/26 6:14:17 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

    License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme diseaseAgreement builds on Company's expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosisCompany continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company" or "60 Degrees Pharma"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced tha

    7/8/26 8:01:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

    WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (NCT06656351), following a review of safety data from the first six patients from baseline through Day 30. The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of tafenoquine (loading dose of 200 mg per day for four days, then 200 mg weekly through Day 90) in patients with severe persiste

    7/1/26 8:02:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

    License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company's recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S. WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company" or "60 Degrees Pharma"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida State University to commence large-scal

    6/11/26 8:03:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTP
    Financials

    Live finance-specific insights

    View All

    VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (NASDAQ:VSEE) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV on November 30. Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:VSEE: https://www.redchip.com/assets/access/vsee_accessSXTP: https://www.redchip.com/assets/access/sxtp_accessIn an exclusive interview, Imo Aisiku, M.D., co-CEO and Chairman of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated so

    12/2/24 4:05:00 PM ET
    $SXTP
    $VSEE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services

    60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on

    11/22/24 9:00:00 AM ET
    $CANF
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV

    MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: •  Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/

    9/1/23 10:00:00 AM ET
    $GENE
    $SXTP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $SXTP
    SEC Filings

    View All

    60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    7/20/26 4:05:19 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    7/9/26 4:05:54 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by 60 Degrees Pharmaceuticals Inc.

    DEF 14A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    7/2/26 4:05:36 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SXTP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by 60 Degrees Pharmaceuticals Inc.

    SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/14/24 3:37:18 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc.

    SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/13/24 4:01:15 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc. (Amendment)

    SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    5/7/24 7:19:08 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care